Samsung BioLogics Co Ltd

XKRX:207940 (Korea (the Republic of))  
â‚© 781000.00 (-1.14%) Apr 19
64.81
P/B:
5.65
Market Cap:
â‚© 55.59T ($ 40.44B)
Enterprise V:
â‚© 55.44T ($ 40.33B)
Volume:
55.68K
Avg Vol (2M):
62.13K
Warning! GuruFocus detected 1 Medium warning sign with 207940. Try a 7-Day Free Trial to check it out.
Volume:
55.68K
Market Cap â‚©:
55.59T
Market Cap $:
40.44B
64.81
Avg Vol (2M):
62.13K
Enterprise Value â‚©:
55.44T
Enterprise Value $:
40.33B
PB Ratio:
5.65
Alerts Website Sources Stock PDF
Dataset
Financial Download Manual of Stocksâ„¢

Business Description

Samsung BioLogics Co Ltd

ISIN : KR7207940008
https://www.samsungbiologics.com
125, Cheomdan-daero, Yeonsu-gu,, Incheon, KOR
Compare
Compare
XKRX:068270XKRX:326030XKRX:302440XKRX:028300XKRX:196170XKRX:145020XKRX:048410XKRX:086900XKRX:214450XKRX:141080OCSE:NOVO BVRTXREGNASX:CSLSGENMRNAHKSE:02269XBRU:ARGXBNTXBGNE
Traded in other countries / regions
207940.Korea
IPO Date
2016-11-10
Description
Samsung BioLogics Co Ltd engaged in development and manufacturing of bio-healthcare products.The Company works namely in Process Development, cGMP Manufacturing, Aseptic Fill and Finish.

Financial Strength

7/10
Name Current Vs Industry Vs History
Cash-To-Debt 1.08
Equity-to-Asset 0.61
Debt-to-Equity 0.19
Debt-to-EBITDA 1.13
Interest Coverage 13.65
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 6.36
Distress
Grey
Safe
Beneish M-Score -2.76
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

10/10
Name Current Vs Industry Vs History
3-Year Revenue Growth Rate 43.9
3-Year EBITDA Growth Rate 55.1
3-Year EPS without NRI Growth Rate 48.7
3-Year FCF Growth Rate 114.3
3-Year Book Growth Rate 26.2
Future 3-5Y Total Revenue Growth Rate 14.21

Momentum Rank

6/10
Name Current Vs Industry Vs History
5-Day RSI 33.42
9-Day RSI 33.87
14-Day RSI 37.9
6-1 Month Momentum % 19.27
12-1 Month Momentum % 7.61

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.33
Quick Ratio 0.69
Cash Ratio 0.49
Days Inventory 483.74
Days Payable 28.93

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -2.1
Shareholder Yield % -0.18

Profitability Rank

7/10
Name Current Vs Industry Vs History
Gross Margin % 48.8
Operating Margin % 30.14
Net Margin % 23.22
FCF Margin % 15.18
ROE % 9.16
ROA % 5.32
ROIC % 6.57
ROC (Joel Greenblatt) % 27.8
ROCE % 9.9
Years of Profitability over Past 10-Year 7

GF Value Rank

4/10
Name Current Vs Industry Vs History
PE Ratio 64.81
PE Ratio without NRI 64.68
Shiller PE Ratio 105.15
Price-to-Owner-Earnings 40.25
PEG Ratio 1.64
PS Ratio 15.05
PB Ratio 5.65
Price-to-Tangible-Book 13.9
Price-to-Free-Cash-Flow 99.09
Price-to-Operating-Cash-Flow 33.36
EV-to-EBIT 46.14
EV-to-Forward-EBIT 35.79
EV-to-EBITDA 32.78
EV-to-Forward-EBITDA 30.37
EV-to-Revenue 15.01
EV-to-Forward-Revenue 12.81
EV-to-FCF 99.98
Price-to-Projected-FCF 6.87
Price-to-Peter-Lynch-Fair-Value 2.59
Price-to-Graham-Number 6.32
Earnings Yield (Greenblatt) % 2.16
FCF Yield % 1.01
Forward Rate of Return (Yacktman) % 20.13

Financials (Next Earnings Date:2024-07-12 Est.)

XKRX:207940's 30-Y Financials
AAPL
Income Statement Breakdown
No Enough Data
AAPL
Balance Sheet Breakdown
No Enough Data
AAPL
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Samsung BioLogics Co Ltd Executives

Details

GF Value: â‚©1569839.21

XKRX:207940

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil â‚©) 3,694,588.767
EPS (TTM) (â‚©) 12050
Beta 0.46
Volatility % 20.24
14-Day RSI 37.9
14-Day ATR (â‚©) 17927.646437
20-Day SMA (â‚©) 810600
12-1 Month Momentum % 7.61
52-Week Range (â‚©) 668000 - 880000
Shares Outstanding (Mil) 71.17

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Samsung BioLogics Co Ltd Filings

Filing Date Document Date Form
No Filing Data

Samsung BioLogics Co Ltd Stock Events

Financials Calendars
Event Date Price(â‚©)
No Event Data

Samsung BioLogics Co Ltd Frequently Asked Questions

What is Samsung BioLogics Co Ltd(XKRX:207940)'s stock price today?
The current price of XKRX:207940 is â‚©781000.00. The 52 week high of XKRX:207940 is â‚©880000.00 and 52 week low is â‚©668000.00.
When is next earnings date of Samsung BioLogics Co Ltd(XKRX:207940)?
The next earnings date of Samsung BioLogics Co Ltd(XKRX:207940) is 2024-07-12 Est..
Does Samsung BioLogics Co Ltd(XKRX:207940) pay dividends? If so, how much?
Samsung BioLogics Co Ltd(XKRX:207940) does not pay dividend.

Press Release

Subject Date
No Press Release
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.